RAD21 and ductal breast carcinoma in situ: Expression of RAD21 in DCIS ranged from negative (2/60 cases, 3%) to heterogenous staining (30/60 cases, 50%) and homogenous strong staining (28/60 cases, 47%) (Figure 1A).